Last reviewed: June 22, 2026
Last updated: June 22, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide qualification depends on multiple clinical criteria rather than a single weight or BMI number. The FDA-approved version (Ozempic for diabetes, Wegovy for weight loss) established initial benchmarks, but compounded semaglutide from licensed pharmacies can be prescribed based on broader medical assessment by your healthcare provider.
Start your GLP-1 program with PlexusDx
One all-inclusive price covers your online provider visit, prescription, compounded medication, and shipping — no membership, no hidden fees. Complete a short intake and a licensed provider takes it from there.
Start your intake →
Body Mass Index and Weight Thresholds for Semaglutide
Body Mass Index (BMI) serves as a starting reference point for semaglutide eligibility, though it is not the only qualifying factor. A BMI of 30 or higher generally indicates obesity-range weight, while a BMI of 27 or higher combined with at least one weight-related health condition (such as hypertension or type 2 diabetes) can also support candidacy. Your actual weight in pounds matters less than your weight relative to your height and your overall metabolic health profile.
Compounded semaglutide from PlexusDx-partnered 503A pharmacies may be appropriate even for patients who fall outside traditional BMI cutoffs if they demonstrate significant metabolic dysfunction, insulin resistance, or cardiovascular risk factors. Your healthcare provider will weigh your individual circumstances, current medications, and health goals during the evaluation process. Age, gender, and family history of metabolic disease also inform the clinical decision.
Medical Conditions That Support Semaglutide Candidacy
Type 2 diabetes diagnosis strongly supports semaglutide qualification because the medication was originally developed to lower blood sugar and improve cardiovascular outcomes in this population. Prediabetes—elevated fasting glucose or HbA1c levels above normal but below diabetic range—also represents a qualifying condition, as semaglutide can prevent or delay diabetes onset. High blood pressure, abnormal cholesterol levels, fatty liver disease, and sleep apnea are additional metabolic conditions that may qualify patients regardless of BMI alone.
Polycystic ovary syndrome (PCOS), a condition affecting hormonal balance and insulin sensitivity in women, frequently supports semaglutide eligibility because the medication improves underlying insulin resistance. Prior bariatric surgery patients seeking additional weight loss support and individuals with a strong family history of type 2 diabetes or heart disease are also commonly considered candidates. Each condition strengthens the clinical rationale for therapy.
Cardiovascular Health and Risk Factor Assessment
Cardiovascular risk factors—including smoking status, family history of heart attack or stroke, sedentary lifestyle, and elevated inflammation markers—play a key role in semaglutide eligibility determination. Patients with established heart disease or prior cardiovascular events may qualify based on semaglutide's proven benefit in reducing heart attack and stroke risk in clinical trials. Your provider will review blood pressure, cholesterol panel results, and other cardiac markers as part of the comprehensive assessment.
Metabolic syndrome, defined as a cluster of conditions including central obesity, hypertension, elevated triglycerides, and insulin resistance, represents a strong indication for semaglutide therapy. Studies demonstrate that GLP-1 receptor agonists like semaglutide improve multiple metabolic syndrome components simultaneously. PlexusDx providers evaluate your full cardiovascular profile to ensure semaglutide fits your overall health strategy.
Current Medications and Health Status Considerations
Existing medications for diabetes, high blood pressure, or cholesterol must be reviewed before starting semaglutide because the medication may require dose adjustments in your other therapies. For example, if you take insulin or certain diabetes pills, your blood sugar medication dosages may need to decrease once semaglutide begins working. Kidney function testing and liver health screening are standard parts of the pre-treatment evaluation to ensure semaglutide is safe for your body.
A personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome (MEN2) would exclude you from semaglutide therapy, as the medication carries a theoretical thyroid cancer risk in this population. Pregnancy and breastfeeding are contraindications, though semaglutide does not affect future fertility. Chronic pancreatitis, severe gallbladder disease, or active gastrointestinal disorders require careful consideration and provider discussion before treatment begins.
How PlexusDx Evaluates Your Semaglutide Qualification
PlexusDx uses a personalized assessment model that goes beyond BMI alone, evaluating your metabolic markers, medication list, and health history through secure telemedicine consultations with licensed providers. The evaluation process includes review of recent lab work, vital signs, and your response to previous weight loss attempts. Your provider documents the medical necessity for compounded semaglutide from a licensed 503A pharmacy, which serves all 50 states without requiring insurance.
The optional Precision Peptide Genetic Test ($298) maps 14 metabolic pathways and 49 peptides to reveal your individual response patterns to GLP-1 therapy and other weight loss mechanisms. Genetic variants in genes like GIPR and FTO relate to the biological pathways these medications act on, which is context for a conversation with your provider rather than a prediction. This genetic insight personalizes your treatment plan beyond standard clinical criteria.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437 , FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.
Frequently Asked Questions
Do I need to be diabetic to qualify for semaglutide through PlexusDx?
No. While type 2 diabetes qualifies you, many non-diabetic patients with obesity, prediabetes, metabolic syndrome, or cardiovascular risk factors also meet candidacy criteria. Your PlexusDx provider evaluates your complete health profile, not just diabetes status, to determine eligibility for compounded semaglutide at $189/mo month-to-month, or from $149/mo on the 6-month plan.
What happens if my BMI is below 30 but I have other health conditions?
A BMI below 30 does not disqualify you if you have weight-related conditions such as hypertension, type 2 diabetes, prediabetes, or significant cardiovascular risk factors. Clinical guidelines support semaglutide use in these situations because the medication addresses underlying metabolic dysfunction beyond simple weight reduction. Your provider will document the medical necessity.
How quickly can I start semaglutide if I'm approved?
After your telemedicine consultation with a PlexusDx provider confirms eligibility, you can begin treatment within days. Compounded semaglutide is shipped from licensed 503A pharmacies with no membership fees, insurance requirements, or membership delays. Your first injection or oral dose typically arrives shortly after your prescription is filled.
Are there any conditions that disqualify me from semaglutide?
Personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome (MEN2), pregnancy, breastfeeding, and severe acute pancreatitis are contraindications. Severe kidney or liver disease may also limit eligibility. Your provider will discuss your complete medical history to identify any absolute contraindications.
How does the Precision Peptide Genetic Test help determine if semaglutide is right for me?
The genetic test ($298) identifies your unique variants in GIPR, FTO, and MC4R genes, mapping the appetite-regulation and metabolic pathways that GLP-1 signaling runs through. This insight helps PlexusDx customize your dosing strategy or suggest combination therapies like GLP-Squared for optimal results tailored to your peptide pathways.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Optimizing Your Treatment: Do I Still Take My Metformin with Ozempic?
Navigating Weight Loss and Glaucoma: Can You Take Ozempic If You Have Glaucoma?